Phar­ma com­pa­nies delist patents from FDA's Or­ange Book fol­low­ing FTC chal­lenges

At least three phar­ma com­pa­nies have re­quest­ed to pull patents from an FDA data­base af­ter the Fed­er­al Trade Com­mis­sion chal­lenged more than 100 patents it said were im­prop­er­ly list­ed.

The phar­ma in­dus­try has been un­der in­creased scruti­ny from the FTC this year, in­clud­ing dis­putes last month about patents for brand-name asth­ma in­halers, ep­i­neph­rine au­toin­jec­tors and oth­er drugs. And FTC chair Lina Khan has said that wrong­ful­ly-list­ed patents un­der­mine “fair and hon­est com­pe­ti­tion” and can dri­ve up the cost of health­care for Amer­i­cans who use in­halers and EpiPens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER